These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34659242)

  • 81. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
    Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
    Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Serial transplantation resulting in tolerance to an unrelated cord blood graft.
    Goebel WS; Nelson RP; Brahmi Z; Gowan DJ; Towell PJ; Robertson KA; Haut PR
    Transplantation; 2006 Jun; 81(11):1596-9. PubMed ID: 16770250
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE
    Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
    [TBL] [Abstract][Full Text] [Related]  

  • 84. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
    Luznik L; O'Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; Huff CA; Matsui W; Bolaños-Meade J; Borrello I; Powell JD; Harrington E; Warnock S; Flowers M; Brodsky RA; Sandmaier BM; Storb RF; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):641-50. PubMed ID: 18489989
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Chimerism studies as an approach for the induction of tolerance to extremity allografts.
    Muramatsu K; Kuriyama R; You-Xin S; Hashimoto T; Matsunaga T; Taguchi T
    J Plast Reconstr Aesthet Surg; 2008 Sep; 61(9):1009-15. PubMed ID: 18573704
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A nonlethal conditioning approach to achieve engraftment of xenogeneic rat bone marrow in mice and to induce donor-specific tolerance.
    Neipp M; Exner BG; Ildstad ST
    Transplantation; 1998 Oct; 66(8):969-75. PubMed ID: 9808477
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
    Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
    Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
    Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
    Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
    Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Flt3-L augments the engraftment of donor-derived bone marrow cells when combined with sublethal irradiation and costimulatory (CD28/B7 and CD40/CD40L) blockade.
    Woodward JE; Salam A; Logar AJ; Schaefer AT; Rao AS
    Cell Transplant; 2002; 11(2):147-59. PubMed ID: 12099638
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CD8(+), alphabeta-TCR(+), and gammadelta-TCR(+) cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow.
    Xu H; Exner BG; Cramer DE; Tanner MK; Mueller YM; Ildstad ST
    J Immunol; 2002 Feb; 168(4):1636-43. PubMed ID: 11823491
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.
    Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M
    Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.
    Llosa NJ; Cooke KR; Chen AR; Gamper CJ; Klein OR; Zambidis ET; Luber B; Rosner G; Siegel N; Holuba MJ; Robey N; Hayashi M; Jones RJ; Fuchs E; Holdhoff M; Loeb DM; Symons HJ
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2127-2136. PubMed ID: 28807769
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mechanisms of cyclophosphamide-induced tolerance to IE-encoded alloantigens--evidence of clonal deletion in MHC antigen-reactive cells for skin allograft rejection.
    Tomita Y; Ayukawa K; Yoshikai Y; Nomoto K
    Transplantation; 1992 Mar; 53(3):602-12. PubMed ID: 1347961
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Effect of chemical modification of grafts on the survival improvement post haploidentical bone marrow transplantation in mice].
    Yang G; Tang SQ; Zhang XF; Liu LZ; Huang DS; Wang JW
    Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):684-7. PubMed ID: 15482672
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Facilitating cells as a venue to establish mixed chimerism and tolerance.
    Jacquet EG; Schanie CL; Fugier-Vivier I; Willer SS; Ildstad ST
    Pediatr Transplant; 2003 Oct; 7(5):348-57. PubMed ID: 14738294
    [TBL] [Abstract][Full Text] [Related]  

  • 99. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.
    Luznik L; Fuchs EJ
    Immunol Res; 2010 Jul; 47(1-3):65-77. PubMed ID: 20066512
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [HLA-haploidentical transplantation with post-transplant cyclophosphamide].
    Sugita J
    Rinsho Ketsueki; 2017; 58(10):2124-2134. PubMed ID: 28978857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.